Table 3.

Current prospective research trials using hydroxyurea therapy for SCA in sub-Saharan Africa

Clinical and statusPerformance sitesNo. of participantsStudy end points
Sickle Cell Disease–Stroke Prevention in Nigeria Trial (SPIN)NCT01801423Kano, Nigeria40TCD velocity
Active, not recruiting
Realizing Effectiveness of Hydroxyurea Across Continents (REACH)NCT01966731Luanda, Angola; Kinshasa, DRC; Kilifi, Kenya; Mbale Uganda600Adherence, toxicity, dosing
Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM)NCT01976416Kampala, Uganda200Malaria events
Active, not recruiting
Risk Clinical Stratification of Sickle Cell Disease in Nigeria: Assessment of Efficacy/Safety of Hydroxyurea TreatmentNCT02149537Ibadan, Nigeria40Cytopenia
Enrolling by invitation
Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II (SPRING)NCT02560935Kano, Nigeria440Stroke occurrence
Low Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa (SPRINT)NCT02675790Kano, Nigeria60Stroke recurrence
Not yet recruiting